We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Roche Acquires High-Precision Dissection Technology from AvanSci Bio

By LabMedica International staff writers
Posted on 15 Dec 2014
Print article
Roche Diagnostics of the Roche group (Basel, Switzerland) has signed a definitive Asset Purchase Agreement with AvanSci Bio (Salt Lake City, UT, USA) for all products associated with the high-performance microdissection of slide-mounted tissue sections for subsequent molecular analysis.

The system consists of instrumentation, software, and consumables used by researchers and clinicians to extract specific areas of tissue with high precision and purity for subsequent molecular analysis, including real-time PCR, microarrays, and sequencing. For example, tumor tissue staining gives important information about both tissue context and spatial relationships, as well as about tumor heterogeneity stemming from evolution of multiple subclones within the tumor. Information obtained from stained areas enable to pinpoint and extract more precise regions of interest within a tissue, resulting in purer samples of sufficient quantity that can then be used for sequencing. In addition, the analytical sensitivity of sequencing improves with higher sample purity, as does subsequent data analysis and interpretation.

AvanSci Bio's patent-pending technology includes the automated “MilliSect” instrument, which targets a 100 mm2 to 100 µm2 level of resolution (what AvanSci refers to as "meso" dissection range). This unique technology is highly precise, easy to use, and very affordable when compared to manual dissection methods and laser microdissection systems. The MilliSect system's high specificity and quality enables a greater than 90% tumor enriched sample for molecular analysis.

The system will be tested at select customer sites in 2015 as part of a broader development program for a future-generation instrument.

“This innovative system will expand our diagnostic tool kit, allowing us to link the diagnostic hematoxylin and eosin (H&E) stain with sequencing analysis through high-quality sample preparation,” said Dan Zabrowski, head of Roche Tissue Diagnostics and Sequencing Solutions, “It will also enable us to meet the critical challenge of tumor heterogeneity.”

“We are very pleased that Roche has decided to pursue this Asset Purchase Agreement with AvanSci Bio,” said Rob Perry, CEO, AvanSci Bio, “We see Roche as the leader in tissue-based diagnostics, molecular diagnostics, and oncology, as well as tumor sample enrichment technology, which puts them in a unique position to maximize the impact our technology will have on the rapidly evolving field of sequencing and in improving patient care.”

As the challenge of tumor heterogeneity is addressed through slide-based tissue diagnostic technologies and as the analytical sensitivity of next-generation sequencing improves, patients may benefit through more accurate and effective targeted therapies. Roche continues to invest in bridging anatomical pathology and genomics as laboratories increasingly rely on pure, tumor-enriched slide-mounted tissue samples for sensitive and efficient molecular analysis.

Related Links:

Roche
AvanSci Bio


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.